Skye Bioscience to Present Expanded Preclinical CB1 Antibody Data at the American Diabetes Association’s 85th Scientific Sessions

Core Insights - Skye Bioscience, Inc. is set to present new data on nimacimab at the American Diabetes Association's 85th Scientific Sessions, highlighting its focus on obesity and metabolic health disorders [1][2] Presentation Details - Skye's CEO, CMO, and CSO will participate in an invitation-only panel at the Evercore event during the ADA conference [3] - A symposium presentation titled "Mechanistic Insights into Weight Loss and Metabolic Regulation of Obese Mice Treated with Nimacimab" will be held on June 22, 2025, showcasing the therapeutic potential of nimacimab [4] - A poster presentation will discuss how nimacimab promotes metabolic homeostasis in a diet-induced obesity mouse model, emphasizing weight loss and hormonal regulation [5] Company Overview - Skye Bioscience is dedicated to developing next-generation therapeutics targeting G-protein coupled receptors, with a focus on obesity and metabolic health [6][7] - The company is conducting a Phase 2 clinical trial for nimacimab, assessing its effects both alone and in combination with a GLP-1R agonist [7]